Effect of Zhengyuan Capsule Combined with Anlotinib on Efficacy,Cancer-Related Fatigue and Immune Function in Patients with Advanced Non-Small Cell Lung Cancer after Second-Line Treatment
Objective:To investigate the effect of zhengyuan capsule combine with anlotinib on efficacy,cancer-related fatigue and immune function in patients with advanced non-small cell lung cancer(NSCLC)after second-line treatment.Methods:103 patients with advanced NSCLC who were progressed driver gene negative after second-line treatment in Jinling Hospital Affiliated to Medical School of Nanjing University from April 2020 to May 2023 were selected,and patients were divided into control group(treated with an-lotinib,n=51)and study group(treated with zhengyuan capsules combine with anlotinib,n=52)by random number table method.The clinical efficacy,Piper fatigue scale,Karnofsky functional status score(KPS),serum tumor markers[cytokeratin 19 fragment antigen 21-1(CYFRA21-1),carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125)],immune function indicators[natural killer(NK)cells,T lymphocyte subsets:CD4+,CD8+,CD4+/CD8+]were compared between two groups,and the occurrence of adverse reactions during the treatment in two groups was observed.Results:Compared with control group,the objective response rate(ORR)and disease control rate(DCR)in study group were higher(P＜0.05).The Piper fatigue scale score in study group after treatment was lower than that in control group,KPS score was higher than that in control group.The decrease levels of serum tumor markers CYFRA21-1,CEA,and CA125 in study group were higher than those in control group(P＜0.05),immune function indicators,the decrease rate of NK cells,CD4+,CD4+/CD8+in study group was lower than those in control group,and the increase rate of CD8+was lower than that in control group(P＜0.05).There was no difference in the incidence of adverse reactions between two groups during treatment(P＞0.05).Conclusion:Zhenyuan capsule combine with anlotinib can improve the clinical efficacy of advanced NSCLC patients with progression driver gene negative after second-line treatment,which can reducing the level of tumor markers,reducing cancer-related fatigue,improving quality of life and improving immune function.
Zhengyuan capsuleAnlotinibAdvanced non-small cell lung cancerEfficacyCancer-related fatigueImmune function
NETL
NSTL
万方数据
